Goldman Sachs’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Goldman Sachs’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-104,200	Closed	-$415K	–	6325
2022 Q4	$415K	Hold	104,200	–	–	﹤0.01%	4973
2022 Q3	$693K	Buy	+104,200	New	+$642K	﹤0.01%	4764

Goldman Sachs's MRNS Position: Q1 2025 in Review

Goldman Sachs sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 52,328 shares — an estimated $28K sold.

Goldman Sachs first reported a position in MRNS in Q3 2014 and held it in 35 quarters. The position peaked at $7.61M in Q1 2019. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

Goldman Sachs reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
Goldman Sachs sold 52,328 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $28K.
Goldman Sachs first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 35 quarters.
Goldman Sachs's Marinus Pharmaceuticals, Inc position peaked at $7.61M in Q1 2019.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.